Urinary tract infection (UTI) refers to the bacterial infection in any part of the urinary system including kidneys, ureters, bladder, and urethra. It is one of the most common types of bacterial infections found majorly in women. The rising prevalence of urinary tract infections (UTI) across the globe can be attributed to increasing geriatric population, unhealthy lifestyle habits such as lack of personal hygiene, and increasing use of catheters. Advancements in therapeutics for effective treatment of urinary tract infections is also boosting the market growth.

The global urinary tract infection therapeutic market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The urinary tract infection therapeutic market is witnessing significant growth owing to rising geriatric population globally. As per estimates, by 2030, approximately 1.5 billion people will be aged over 65 years worldwide. Individuals aged 65 years or above are at a significantly higher risk of developing UTIs due to weakening of the bladder muscles and urethra with age. This has led to increasing demand for effective treatment options for urinary tract infections in the geriatric population. Another major driver fueling the market growth is increasing use of catheters. Catheterization procedures disrupt the normal flow of urine and provide an entry point for bacteria to attach and infect the bladder. This is increasing the risk of catheter-associated urinary tract infections.

SWOT Analysis

Strength: The urinary tract infection therapeutic market offers wide range of treatment options for patients suffering from UTI. This provides physicians with multiple drugs to choose from according to the severity of infection and patient's medical history. Secondly, rise in awareness campaigns have educated people about the symptoms of UTI and importance of early diagnosis and treatment. Thirdly, technological advancements have enabled development of novel drugs with improved efficacy and reduced side effects.

Weakness: High cost of branded drugs puts financial burden on patients. Secondly, increasing antibiotic resistance poses treatment challenges for physicians.

Opportunity: Growing geriatric population prone to recurrent UTIs presents sizable patient pool. Secondly, developing economies offer immense growth prospects due to increasing healthcare expenditures.

Threats: Stringent regulatory approvals delay market entry of new drugs. Secondly, safety issues pertaining to certain drugs negatively impact their demand.

Key Takeaways

The global urinary tract infection therapeutic market is expected to witness high growth over the forecast period owing to rising prevalence of UTIs worldwide. The global urinary tract infection therapeutic market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030.

Regional analysis: The Asia Pacific region is poised to offer significant lucrative opportunities for market players during the forecast period. Rising geriatric population, improving access to healthcare facilities, and growing awareness about UTIs are some key factors driving the market in the region. China, India, and Japan hold substantial shares in the regional market.

Key players: Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. These companies have robust product portfolios and global sales networks to cater to the bulk of demand. They are continuously striving to develop more effective drugs through extensive R&D activities.